-
Je něco špatně v tomto záznamu ?
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
G. Lerner, H. Tang, K. Singh, R. Golestani, S. St Claire, PA. Humphrey, D. Lannin, R. Janostiak, M. Harigopal
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- lymfatické metastázy MeSH
- nádorové biomarkery metabolismus MeSH
- nádory prsu * metabolismus MeSH
- racemasy a epimerasy MeSH
- receptor erbB-2 metabolismus MeSH
- receptory pro estrogeny metabolismus MeSH
- receptory progesteronu metabolismus MeSH
- triple-negativní karcinom prsu * diagnóza MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Carcinoma with apocrine differentiation (AC) is a subtype of breast carcinoma with apocrine features in >90% of the tumor. Molecular studies demonstrate AC has high expression of androgen receptor (AR) mRNA. Pure AC lack estrogen receptor (ER), progesterone receptor (PR), and express AR, with variable human epidermal growth factor 2 (HER2) status. Currently, in triple negative AC, no targetable therapies or specific diagnostic markers exist. MATERIALS AND METHODS: α-Methylacyl CoA racemase (AMACR) expression was investigated as a marker of apocrine differentiation using a single-plex immunoperoxidase stain, and a novel AMACR/p63 dual stain in a subset of cases, across 1) benign apocrine lesions (apocrine metaplasia, adenosis) 2) apocrine DCIS (ADCIS), 3) AC/ invasive ductal carcinoma (IDC) with apocrine features, 4) non-apocrine triple negative breast cancer (TNBC) and 5) IDC, no special type. A sub-set of cases were evaluated by tissue microarray. RESULTS: AMACR expression was increased in both AC and ADCIS, with minimal expression in benign breast tissue, TNBC and IDC, NST cases. In invasive cases, those with positive AMACR (>5% positivity) were significantly associated with higher histologic grade (P = .006), initial N stage (chi squared 0.044), and lack of ER or PR expression (both P < .001), with no correlation with overall survival. Analysis of TCGA breast cancer datasets revealed AMACR expression was significantly higher in molecularly defined apocrine carcinomas relative to basal and luminal subtypes. Moreover, high AMACR expression predicted worse relapse-free and distant-metastasis free survival, among both ER-/PR-/Her2- and ER-/PR-/Her2+ breast cancer cohorts (log-rank P = .081 and .00011, respectively). CONCLUSION: AMACR represents a promising diagnostic and prognostic marker in apocrine breast lesions. Further study is needed to determine the biologic and clinical significance of this protein in AC.
BIOCEV Charles University Vestec Czech Republic
Department of Surgery Section of Surgical Oncology Yale University School of Medicine New Haven CT
Department of Surgical Pathology Yale University School of Medicine New Haven CT
Yale Pathology Tissue Services Yale University School of Medicine New Haven CT
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004326
- 003
- CZ-PrNML
- 005
- 20230425141306.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clbc.2022.11.012 $2 doi
- 035 __
- $a (PubMed)36577560
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lerner, Gabriel $u Department of Surgical Pathology, Yale University School of Medicine, New Haven, CT
- 245 10
- $a AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers / $c G. Lerner, H. Tang, K. Singh, R. Golestani, S. St Claire, PA. Humphrey, D. Lannin, R. Janostiak, M. Harigopal
- 520 9_
- $a BACKGROUND: Carcinoma with apocrine differentiation (AC) is a subtype of breast carcinoma with apocrine features in >90% of the tumor. Molecular studies demonstrate AC has high expression of androgen receptor (AR) mRNA. Pure AC lack estrogen receptor (ER), progesterone receptor (PR), and express AR, with variable human epidermal growth factor 2 (HER2) status. Currently, in triple negative AC, no targetable therapies or specific diagnostic markers exist. MATERIALS AND METHODS: α-Methylacyl CoA racemase (AMACR) expression was investigated as a marker of apocrine differentiation using a single-plex immunoperoxidase stain, and a novel AMACR/p63 dual stain in a subset of cases, across 1) benign apocrine lesions (apocrine metaplasia, adenosis) 2) apocrine DCIS (ADCIS), 3) AC/ invasive ductal carcinoma (IDC) with apocrine features, 4) non-apocrine triple negative breast cancer (TNBC) and 5) IDC, no special type. A sub-set of cases were evaluated by tissue microarray. RESULTS: AMACR expression was increased in both AC and ADCIS, with minimal expression in benign breast tissue, TNBC and IDC, NST cases. In invasive cases, those with positive AMACR (>5% positivity) were significantly associated with higher histologic grade (P = .006), initial N stage (chi squared 0.044), and lack of ER or PR expression (both P < .001), with no correlation with overall survival. Analysis of TCGA breast cancer datasets revealed AMACR expression was significantly higher in molecularly defined apocrine carcinomas relative to basal and luminal subtypes. Moreover, high AMACR expression predicted worse relapse-free and distant-metastasis free survival, among both ER-/PR-/Her2- and ER-/PR-/Her2+ breast cancer cohorts (log-rank P = .081 and .00011, respectively). CONCLUSION: AMACR represents a promising diagnostic and prognostic marker in apocrine breast lesions. Further study is needed to determine the biologic and clinical significance of this protein in AC.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory prsu $x metabolismus $7 D001943
- 650 12
- $a triple-negativní karcinom prsu $x diagnóza $7 D064726
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a receptor erbB-2 $x metabolismus $7 D018719
- 650 _2
- $a receptory progesteronu $x metabolismus $7 D011980
- 650 _2
- $a receptory pro estrogeny $x metabolismus $7 D011960
- 650 _2
- $a racemasy a epimerasy $7 D019998
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tang, Haiming $u Department of Surgical Pathology, Yale University School of Medicine, New Haven, CT
- 700 1_
- $a Singh, Kamaljeet $u Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI
- 700 1_
- $a Golestani, Reza $u Department of Surgical Pathology, Yale University School of Medicine, New Haven, CT
- 700 1_
- $a St Claire, Samantha $u Yale Pathology Tissue Services, Yale University School of Medicine, New Haven, CT
- 700 1_
- $a Humphrey, Peter A $u Department of Surgical Pathology, Yale University School of Medicine, New Haven, CT
- 700 1_
- $a Lannin, Donald $u Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, New Haven, CT
- 700 1_
- $a Janostiak, Radoslav $u BIOCEV, Charles University, Vestec, Czech Republic
- 700 1_
- $a Harigopal, Malini $u Department of Surgical Pathology, Yale University School of Medicine, New Haven, CT
- 773 0_
- $w MED00188740 $t Clinical breast cancer $x 1938-0666 $g Roč. 23, č. 2 (2023), s. 199-210
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36577560 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141303 $b ABA008
- 999 __
- $a ok $b bmc $g 1924794 $s 1190535
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 2 $d 199-210 $e 20221205 $i 1938-0666 $m Clinical breast cancer $n Clin Breast Cancer $x MED00188740
- LZP __
- $a Pubmed-20230418
